WO2019173787A8 - Constructions d'administration dérivées de toxines pour administration orale - Google Patents

Constructions d'administration dérivées de toxines pour administration orale Download PDF

Info

Publication number
WO2019173787A8
WO2019173787A8 PCT/US2019/021474 US2019021474W WO2019173787A8 WO 2019173787 A8 WO2019173787 A8 WO 2019173787A8 US 2019021474 W US2019021474 W US 2019021474W WO 2019173787 A8 WO2019173787 A8 WO 2019173787A8
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
derived
toxin
constructs
bacterial toxin
Prior art date
Application number
PCT/US2019/021474
Other languages
English (en)
Other versions
WO2019173787A1 (fr
Inventor
Keyi LIU
Julia Dawn MACKAY
Weijun Feng
Thomas Carl HUNTER
Randall J. Mrsny
Original Assignee
Applied Molecular Transport Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Transport Inc. filed Critical Applied Molecular Transport Inc.
Priority to DK19717013.7T priority Critical patent/DK3762009T3/da
Priority to EA202092126A priority patent/EA202092126A1/ru
Priority to SI201930291T priority patent/SI3762009T1/sl
Priority to EP19717013.7A priority patent/EP3762009B1/fr
Priority to KR1020207028975A priority patent/KR20210076881A/ko
Priority to CN201980031164.1A priority patent/CN112105376A/zh
Priority to EP23192492.9A priority patent/EP4316586A3/fr
Priority to ES19717013T priority patent/ES2920428T3/es
Priority to PL19717013.7T priority patent/PL3762009T3/pl
Priority to EP22165874.3A priority patent/EP4082558B1/fr
Priority to AU2019230230A priority patent/AU2019230230A1/en
Priority to CA3093386A priority patent/CA3093386A1/fr
Priority to SG11202009925PA priority patent/SG11202009925PA/en
Priority to CA3119179A priority patent/CA3119179A1/fr
Priority to JP2021525126A priority patent/JP7487193B2/ja
Priority to PCT/US2019/050708 priority patent/WO2020096695A1/fr
Priority to TW108132886A priority patent/TW202031297A/zh
Priority to SG11202104734YA priority patent/SG11202104734YA/en
Priority to AU2019374703A priority patent/AU2019374703A1/en
Priority to BR112021009001A priority patent/BR112021009001A8/pt
Priority to IL282986A priority patent/IL282986B2/en
Priority to EP19881649.8A priority patent/EP3826682A4/fr
Priority to KR1020217017372A priority patent/KR20210110800A/ko
Priority to MX2021005382A priority patent/MX2021005382A/es
Priority to CN201980088247.4A priority patent/CN113347997A/zh
Publication of WO2019173787A1 publication Critical patent/WO2019173787A1/fr
Priority to AU2019377117A priority patent/AU2019377117A1/en
Priority to MX2021005346A priority patent/MX2021005346A/es
Priority to KR1020217017210A priority patent/KR20210110294A/ko
Priority to TW108140533A priority patent/TW202031678A/zh
Priority to CA3119060A priority patent/CA3119060A1/fr
Priority to SG11202104721RA priority patent/SG11202104721RA/en
Priority to CN201980088287.9A priority patent/CN113423722A/zh
Priority to DK19207825.1T priority patent/DK3650037T3/da
Priority to EP22159495.5A priority patent/EP4083058A3/fr
Priority to ES19207825T priority patent/ES2911075T3/es
Priority to BR112021009003-7A priority patent/BR112021009003A2/pt
Priority to EP19207825.1A priority patent/EP3650037B1/fr
Priority to PT192078251T priority patent/PT3650037T/pt
Priority to PCT/US2019/060356 priority patent/WO2020097394A1/fr
Priority to JP2021525169A priority patent/JP2022506990A/ja
Priority to PL19207825T priority patent/PL3650037T3/pl
Priority to US16/686,671 priority patent/US20200140511A1/en
Priority to IL277209A priority patent/IL277209A/en
Priority to US17/015,011 priority patent/US11426466B2/en
Priority to IL282987A priority patent/IL282987B2/en
Priority to CL2021001209A priority patent/CL2021001209A1/es
Priority to CONC2021/0007359A priority patent/CO2021007359A2/es
Priority to CONC2021/0007402A priority patent/CO2021007402A2/es
Publication of WO2019173787A8 publication Critical patent/WO2019173787A8/fr
Priority to US17/868,077 priority patent/US20230158163A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des constructions d'administration non naturelles isolées comprenant une construction d'administration dérivée d'une toxine bactérienne couplée à un cargo thérapeutique biologiquement actif; la construction d'administration étant apte à administrer le cargo biologiquement actif par le biais d'un transport de transcytose à travers une cellule épithéliale; et la construction d'administration ne comprenant pas de domaine de translocation dérivé de toxine bactérienne ou de domaine catalytique dérivé de toxine bactérienne (cytotoxique).
PCT/US2019/021474 2018-03-08 2019-03-08 Constructions d'administration dérivées de toxines pour administration orale WO2019173787A1 (fr)

Priority Applications (49)

Application Number Priority Date Filing Date Title
DK19717013.7T DK3762009T3 (da) 2018-03-08 2019-03-08 Toxin-afledte indgivelseskonstrukter til oral indgivelse
EA202092126A EA202092126A1 (ru) 2018-11-07 2019-03-08 Новые полученные из токсинов конструкции доставки для пероральной доставки
SI201930291T SI3762009T1 (sl) 2018-03-08 2019-03-08 Iz toksinov izpeljani dostavni konstrukti za peroralno dostavo
EP19717013.7A EP3762009B1 (fr) 2018-03-08 2019-03-08 Constructions d'administration dérivées de toxines pour administration orale
KR1020207028975A KR20210076881A (ko) 2018-03-08 2019-03-08 경구 전달용 독소-유래 전달 구조체
CN201980031164.1A CN112105376A (zh) 2018-03-08 2019-03-08 用于经口递送的毒素衍生的递送构建体
EP23192492.9A EP4316586A3 (fr) 2018-03-08 2019-03-08 Constructions d'administration dérivées de toxines pour administration orale
ES19717013T ES2920428T3 (es) 2018-03-08 2019-03-08 Constructos de administración derivados de toxinas para la administración oral
PL19717013.7T PL3762009T3 (pl) 2018-03-08 2019-03-08 Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
EP22165874.3A EP4082558B1 (fr) 2018-03-08 2019-03-08 Constructions dérivées de toxine pour l'administration par voie orale
AU2019230230A AU2019230230A1 (en) 2018-03-08 2019-03-08 Toxin-derived delivery constructs for oral delivery
CA3093386A CA3093386A1 (fr) 2018-03-08 2019-03-08 Constructions d'administration derivees de toxines pour administration orale
SG11202009925PA SG11202009925PA (en) 2018-03-08 2019-03-08 Toxin-derived delivery constructs for oral delivery
CA3119179A CA3119179A1 (fr) 2018-11-07 2019-09-11 Supports derives de cholix pour administration orale de chargement heterologue
JP2021525126A JP7487193B2 (ja) 2018-11-07 2019-09-11 異種ペイロードの経口送達のためのコリックス由来担体
PCT/US2019/050708 WO2020096695A1 (fr) 2018-11-07 2019-09-11 Supports dérivés de cholix pour administration orale de chargement hétérologue
TW108132886A TW202031297A (zh) 2018-11-07 2019-09-11 用於經口遞送異種負載之衍生自cholix的載體
SG11202104734YA SG11202104734YA (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
AU2019374703A AU2019374703A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
BR112021009001A BR112021009001A8 (pt) 2018-11-07 2019-09-11 Veículos derivados de cholix para administração oral de carga útil heteróloga
IL282986A IL282986B2 (en) 2018-11-07 2019-09-11 Colics-derivative carriers for oral administration of heterologous cargo
EP19881649.8A EP3826682A4 (fr) 2018-11-07 2019-09-11 Supports dérivés de cholix pour administration orale de chargement hétérologue
KR1020217017372A KR20210110800A (ko) 2018-11-07 2019-09-11 이종성 페이로드의 경구 전달용 콜릭스-유래 담체
MX2021005382A MX2021005382A (es) 2018-11-07 2019-09-11 Vehiculos derivados de cholix para suministro oral de carga util heterologa.
CN201980088247.4A CN113347997A (zh) 2018-11-07 2019-09-11 用于经口递送异源有效载荷的Cholix衍生的携带体
AU2019377117A AU2019377117A1 (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods
MX2021005346A MX2021005346A (es) 2018-11-07 2019-11-07 Constructos de suministro para transcitosis y metodos relacionados.
KR1020217017210A KR20210110294A (ko) 2018-11-07 2019-11-07 통과세포외배출용 전달 구조체 및 관련 방법
TW108140533A TW202031678A (zh) 2018-11-07 2019-11-07 用於胞移作用及相關方法之遞送構築體
CA3119060A CA3119060A1 (fr) 2018-11-07 2019-11-07 Constructions d'administration pour la transcytose et methodes associees
SG11202104721RA SG11202104721RA (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods
CN201980088287.9A CN113423722A (zh) 2018-11-07 2019-11-07 用于胞吞转运的递送构建体及相关方法
DK19207825.1T DK3650037T3 (da) 2018-11-07 2019-11-07 Indgivelseskonstrukter til transcytose og tilhørende fremgangsmåder
EP22159495.5A EP4083058A3 (fr) 2018-11-07 2019-11-07 Constructions d'administration pour la transcytose et procédés associés
ES19207825T ES2911075T3 (es) 2018-11-07 2019-11-07 Constructos de administración para transcitosis y métodos relacionados
BR112021009003-7A BR112021009003A2 (pt) 2018-11-07 2019-11-07 construtos de liberação para transcitose e métodos relacionados.
EP19207825.1A EP3650037B1 (fr) 2018-11-07 2019-11-07 Constructions d'administration pour la transcytose et procédés associés
PT192078251T PT3650037T (pt) 2018-11-07 2019-11-07 Construções de administração para transcitose e métodos relacionados
PCT/US2019/060356 WO2020097394A1 (fr) 2018-11-07 2019-11-07 Constructions d'administration pour la transcytose et méthodes associées
JP2021525169A JP2022506990A (ja) 2018-11-07 2019-11-07 トランスサイトーシスのための送達構築物および関連する方法
PL19207825T PL3650037T3 (pl) 2018-11-07 2019-11-07 Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby
US16/686,671 US20200140511A1 (en) 2018-11-07 2019-11-18 Delivery constructs for transcytosis and related methods
IL277209A IL277209A (en) 2018-03-08 2020-09-08 Structures for administration of toxin derivatives for oral administration
US17/015,011 US11426466B2 (en) 2018-03-08 2020-09-08 Toxin-derived delivery constructs for pulmonary delivery
IL282987A IL282987B2 (en) 2018-11-07 2021-05-06 Delivery constructs for transcytosis and related methods
CL2021001209A CL2021001209A1 (es) 2018-11-07 2021-05-07 Constructos de suministro para transcitosis y métodos relacionados
CONC2021/0007359A CO2021007359A2 (es) 2018-11-07 2021-06-04 Vehículos derivados de cholix para suministro oral de carga útil heteróloga
CONC2021/0007402A CO2021007402A2 (es) 2018-11-07 2021-06-07 Constructos de suministro para transcitosis y métodos relacionados
US17/868,077 US20230158163A1 (en) 2018-03-08 2022-07-19 Toxin-derived delivery constructs

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862640168P 2018-03-08 2018-03-08
US201862640194P 2018-03-08 2018-03-08
US201862640188P 2018-03-08 2018-03-08
US62/640,168 2018-03-08
US62/640,194 2018-03-08
US62/640,188 2018-03-08
US201862756889P 2018-11-07 2018-11-07
US62/756,889 2018-11-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2019/050708 Continuation-In-Part WO2020096695A1 (fr) 2018-11-07 2019-09-11 Supports dérivés de cholix pour administration orale de chargement hétérologue
US17/015,011 Continuation US11426466B2 (en) 2018-03-08 2020-09-08 Toxin-derived delivery constructs for pulmonary delivery

Publications (2)

Publication Number Publication Date
WO2019173787A1 WO2019173787A1 (fr) 2019-09-12
WO2019173787A8 true WO2019173787A8 (fr) 2021-07-01

Family

ID=66102749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/021474 WO2019173787A1 (fr) 2018-03-08 2019-03-08 Constructions d'administration dérivées de toxines pour administration orale

Country Status (4)

Country Link
AU (1) AU2019230230A1 (fr)
CA (1) CA3093386A1 (fr)
PT (1) PT3762009T (fr)
WO (1) WO2019173787A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011302645B2 (en) 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AU2015255834B2 (en) 2014-05-07 2020-05-21 Applied Molecular Transport Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
ES2920428T3 (es) * 2018-03-08 2022-08-03 Applied Molecular Transport Inc Constructos de administración derivados de toxinas para la administración oral
CA3119179A1 (fr) * 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Supports derives de cholix pour administration orale de chargement heterologue
CA3119060A1 (fr) * 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Constructions d'administration pour la transcytose et methodes associees
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021155281A1 (fr) * 2020-01-31 2021-08-05 Applied Molecular Transport Inc. Compositions et méthodes pour le traitement de la maladie cœliaque
AR124877A1 (es) * 2021-02-16 2023-05-17 Applied Molecular Transport Inc Composiciones orales sólidas con zinc
WO2022241167A1 (fr) * 2021-05-12 2022-11-17 Applied Molecular Transport Inc. Constructions d'administration dérivées de toxines bactériennes et utilisations associées
WO2022240407A1 (fr) * 2021-05-12 2022-11-17 Applied Molecular Transport Inc. Constructions d'administration dérivées de toxines bactériennes et utilisations associées
WO2023141527A1 (fr) * 2022-01-21 2023-07-27 Applied Molecular Transport Inc. Constructions d'administration clivables par furine
WO2023196532A1 (fr) * 2022-04-08 2023-10-12 Applied Molecular Transport Inc. Constructions d'il-10/vecteur chimériques pour le traitement de la pochite et procédés d'utilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5807832A (en) 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
ATE206308T1 (de) 1993-02-02 2001-10-15 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
GB9420355D0 (en) 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
NZ335005A (en) 1997-08-01 2000-12-22 Toray Industries Method for stabilizing cytokine using a compound arabic acid or the like
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
PL211886B1 (pl) 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
AU2011302645B2 (en) * 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US8877161B2 (en) 2011-10-19 2014-11-04 Georgia Regents Research Institute, Inc. GM1-like peptides and uses thereof
AU2015255834B2 (en) * 2014-05-07 2020-05-21 Applied Molecular Transport Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo

Also Published As

Publication number Publication date
PT3762009T (pt) 2022-08-22
CA3093386A1 (fr) 2019-09-12
WO2019173787A1 (fr) 2019-09-12
AU2019230230A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
WO2019173787A8 (fr) Constructions d'administration dérivées de toxines pour administration orale
EP4316586A3 (fr) Constructions d'administration dérivées de toxines pour administration orale
EP4233978A3 (fr) Administration par voie orale de substances pharmaceutiques actives
MY157772A (en) Antibody formulation
MX2009010179A (es) Formulaciones estables de anticuerpo.
MX2020006098A (es) Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
EP4083058A3 (fr) Constructions d'administration pour la transcytose et procédés associés
EP3501532A3 (fr) Compositions thérapeutiques comprenant de la frataxine, de la lactoferrine et des enzymes mitochondriales génératrices d'énergie et leurs utilisations
MX2021015757A (es) Metodo para la carga de microorganismos en biomateriales de multiples fases.
WO2019147773A3 (fr) Systèmes de distribution d'un produit, appareil d'ouverture de bec et procédés d'utilisation
WO2019077634A3 (fr) Compositions thérapeutiques de peptides antimicrobiens
WO2010100515A3 (fr) Fractions de ferment de germe de blé
ZA202210024B (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug
MX2021004924A (es) Administracion oral de celulas terapeuticas de mamiferos.
AU2002349234A1 (en) Milk protein biofilm and uses thereof
EP3572061A4 (fr) Récipient pour l'administration, le stockage, la distribution ou le transport d'une protéine faiblement adsorbable ou d'une composition contenant des protéines, et appareil pour la production d'une protéine ou d'une composition de protéines
PE20010676A1 (es) Bacteria acida lactica para el tratamiento y/o profilaxis de la giardiasis
MX2021009443A (es) Composiciones que contienen bacterias productoras de bacillaeno o preparaciones de las mismas.
EA202092126A1 (ru) Новые полученные из токсинов конструкции доставки для пероральной доставки
PT1173592E (pt) Sistema de expressao da proteina microbiana
MX2020006886A (es) Sistema para suministro de medicamento.
AU2017434946A8 (en) Pharmaceutical composition to be used for modification of scalp or skin, healing of wound or modification of hair
MX2023008495A (es) Dispositivo para administracion de farmacos con una unica pieza de union.
AU4749900A (en) Inactivated microorganisms comprising soluble and/or solubilizable substances having pharmacological activity and/or nutritional substances having pharmacological activity, the process for their preparation and their uses thereof
WO2023205527A3 (fr) Dispositifs, systèmes, kits et méthodes d'administration de médicaments à la moelle épinière

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19717013

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3093386

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019717013

Country of ref document: EP

Effective date: 20201008

ENP Entry into the national phase

Ref document number: 2019230230

Country of ref document: AU

Date of ref document: 20190308

Kind code of ref document: A